OBR Daily Commentary

forumImage

CytoDyn Files for Breakthrough Therapy Designation with the FDA for the Use of Leronlimab for the Treatment of Metastatic Triple-Negative Breast Cancer

(CytoDyn) Jan 13, 2020 - CytoDyn Inc., a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the Company has filed for Breakthrough Therapy designation (BTD) with the U.S. Food and Drug Administration (FDA) for the use of leronlimab as an adjuvant therapy for the treatment of metastatic triple-negative breast cancer (mTNBC). The BTD filing is based on data from the first patient in the Company’s mTNBC Phase 1b/2 trial and an additional single-patient trial under an emergency investigational new drug (IND) protocol evaluating leronlimab for the treatment of HER2+ metastatic, stage 4, breast cancer (MBC).

Dean Gesme, MD (Posted: January 13, 2020)

quotesC-C Chemokine Receptors (CCR5 or CD195) are ubiquitous on immune cells and play a significant role in inflammatory disorders and cancer. Antibodies targeting CCR5 are a welcome addition to our antineoplastic armamentarium.quotes

Read Article arrow
Add Comment 1 Comment
forumImage

Radiotherapy Can Be Used In Hard-to-treat Bladder Cancer

(ICR [UK]) Jan 13, 2020 - More targeted forms of radiotherapy can effectively treat bladder cancer which has spread to the lymph nodes of the pelvis, according to a new clinical trial.

Howard Sandler, MD, MS, FASTRO (Posted: January 13, 2020)

quotesRadiotherapy as primary treatment (along with TUR and chemotherapy) is having a bit of a renaissance. The BC2001 study, using 5FU and mitomycin along with radiation, demonstrated a non-cisplatin regimen can be effective. Recently published RTOG 0712 (Coen JJ JCO 2019) showed that single agent gemcitabine can be used. Finally, SWOG/NRG have a large open bladder preserving trial testing whether bladder intact survival can be enhanced with immune checkpoint inhibition. Promising times for bladder preservation!quotes

Read Article arrow
Add Comment 1 Comment
forumImage

Veru's Experimental Drug Reduces Hot Flashes In Men In Mid-Stage Study

(Reuters) Jan 13, 2020 - Veru Inc said on Monday a higher dose of its experimental drug reduced hot flashes in men with advanced prostate cancer after six weeks of treatment, in a mid-stage study.

Tomasz M. Beer, MD, FACP (Posted: January 13, 2020)

quotesHot flashes are a common consequence of hormonal therapy for prostate cancer and strategies to treat them are important for quality of survivorship. It is not surprising that an estrogenic drug would be effective. It will be important to learn more about any side effects that might emerge with additional studies.quotes

Read Article arrow
Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Associate Clinical Professor, Medical Oncology Executi...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...